undamentalytics Newsletter
Sign in

Amarin Corp plc\uk (AMRN) stock

Add to watchlist

Add holding +

NASDAQ: AMRN Nasdaq Pharmaceuticals Next results ~January 14, 2027

D Fundamentals grade

Amarin Corp plc\uk is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$32

Revenue-to-maturity cash-flow model

Base case. Range ~$32–$36 across our lower- and higher-growth cases (0%–5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Amarin Corp plc\uk valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds35 adding, 20 cuttingOf 9 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Amarin Corp plc\uk files

Where Amarin stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $176m, down 22.3% on a year earlier, a steeper fall than the 15.1% decline a quarter earlier. That puts it 48 of 51 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin rose to 21.3% from -9.6% a year earlier. Operating margin widened to -18.2% from -42.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 14, 2027 (estimated)

Amarin Corp plc\uk's trailing-twelve-month revenue fell 22.3% year on year, with a free-cash-flow margin of 21.3%. Where it lags: days sales outstanding of 231 days ranks 56 of 59 pharmaceuticals companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 100% in the quarter to 2026-09-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 24.3 points on a year ago.
  • Strong cash generation. 21.3% of revenue turned into free cash flow, against a median of 10.1% for pharmaceuticals companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Revenue shrinking. Revenue fell 22.3% over the last 12 months.
  • Growth slowing. The growth rate is 7.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -18.2%: costs exceed revenue.
  • Below peers: days sales outstanding. Days sales outstanding of 231 days ranks 56 of 59 pharmaceuticals companies we cover (median 72 days).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
$0.00 against an average estimate of -$0.02: beat by 100.0%
Revenue
$40m, down 20.4% on a year earlier
Share reaction
+6.6% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Guidance given
cash, Cash Equivalents & Short-Term Investments $330m (FY 2026 Expectations)
Next report
October 28, 2026

Amarin Corp plc\uk's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.7%
  • 1 week+0.8%
  • 1 month-2.5%
  • This year-13.1%
  • 1 year-23.1%
  • 5 years-85.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$176M
Operating margin
-18.2%
Net margin
-10.9%
EPS (TTM, diluted)
$-0.91

Growth

Revenue growth
−22.3%
Change in growth rate
−7.2 pts
Share count change
+1.5%

Cash

Free cash flow (TTM)
$37.5M
FCF margin
21.3%
Stock pay % of revenue
4.2%

Earnings

Last results
October 28, 2026
Next results (est.)
January 14, 2027

News & updates

Updated November 1, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Amarin Corp plc\uk valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Amarin Corp plc\uk as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.94 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$32 ~$32–$36 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$8.7–$37 Left out: out of range vs price (0.00x)
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$32 ~$32–$36 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Amarin Corp plc\uk with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$37.80$61.60$80.20$272.20$428.80$97.80$67.40$24.20$17.40$9.80$13.96$12.13
Market value$341m$653m$1.1bn$4.0bn$7.3bn$1.9bn$1.4bn$485m$355m$201m$290m$255m
+ Net debt (− = net cash)−$3m$3m$20m−$169m−$594m−$187m−$219m−$218m−$199m−$121m−$135m−$157m
Enterprise value$338m$655m$1.1bn$3.9bn$6.7bn$1.7bn$1.1bn$268m$155m$80m$155m$98m
Multiples
Price / sales 4.2x5.0x6.0x17.6x17.1x3.0x2.3x1.3x1.2x0.9x1.4x1.4x
Price / earnings ——————175.5x—————
Price / free cash flow ————————51.5x—43.1x6.8x
EV / EBITDA ——————102.4x—————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

28 /100

Weak moat

How hard Amarin Corp plc\uk's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -8.5% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 72.0%, moving by 14.7 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -18.6%; its worst year was -42.5%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 3 of 9 years, at a median -9.6% of revenue.

  • Discipline 8 / 20

    The diluted share count rose 7.0% over five years; stock-based pay has been a median 7.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (33 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current — — $166m −22%
Next — — $176m +6%

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.02 $0.00 +100.0%
Jun 2026 −$0.01 −$0.02 −100.0%
Mar 2026 $0.17 $0.00 −100.0%
Dec 2025 $0.07 $0.01 −85.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 28, 2026
  • Cash, Cash Equivalents & Short-Term Investments FY 2026 Expectations about $330m
    “Cash, Cash Equivalents & Short-Term Investments $302.6 $307.8 $314.6 $323.4 ~$330” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

2 analysts, Oct 2026
Buy00%
Hold00%
Sell2100%

Monthly trend

  1. Oct 2026112
  2. Sep 2026112
  3. Aug 202611

Counts of recommendations published by analysts covering Amarin Corp plc\uk, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.3%
of tradable shares
Days to cover
8.68
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
21%
of shares
Held by insiders
37.2%
of shares
Employees
80
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −25.5%

$16.29 on October 31, 2025 to $12.13

ThenNowEffect
Revenue (last 12 months) $219m $186m −15.1%
P/S multiple 1.5x 1.4x −11.4%
Share count 21m 21m −1.0%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −16.9%

$14.60 on November 3, 2023 to $12.13

ThenNowEffect
Revenue (last 12 months) $346m $186m −46.2%
P/S multiple 0.9x 1.4x +58.7%
Share count 20m 21m −2.7%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AMRN−31%−64%−28%−44%+42%−13%
Industry peers (median)−18%−49%−13%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AMRN17%33%50%17%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AMRN−63%−71%−70%−67%−38%−31%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 98% from December 13, 2019 to March 12, 2025. Getting back needed a 5930% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$11.32 – $16.98
From 52-week high
−28.6%
vs 50-day average
−6.2%
vs 200-day average
−15.2%
Volatility (1 year)
41%
Beta vs S&P 500
0.39

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±7.4%
After a week
4 up, 7 down
typical move ±6.6%
After a month
5 up, 6 down
typical move ±9.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +6.6% 0.0% — —
July 29, 2026 +2.0% +0.1% +3.3% +0.9%
April 29, 2026 −0.2% +1.0% +6.7% +3.8%
February 25, 2026 −9.0% +0.3% −6.3% −5.5%
January 8, 2026 +12.8% +0.7% +6.2% +5.1%
October 29, 2025 −13.4% −1.1% −19.2% −15.7%
July 30, 2025 −0.9% −0.5% +2.7% +5.2%
May 7, 2025 +5.1% +1.1% −0.4% +24.8%
March 12, 2025 −12.8% −0.8% −2.1% −4.3%
October 30, 2024 −4.9% −2.3% −3.3% −16.4%
July 31, 2024 −20.5% +0.2% −15.4% −21.8%
May 1, 2024 0.0% +0.6% −6.5% −5.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Amarin Corp plc\uk in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Amarin Corp plc\uk
$150M $200M $250M $300M $350M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $306.9M Revenue (TTM), FY24 Q1: $277.5M Revenue (TTM), FY24 Q2: $264.8M Revenue (TTM), FY24 Q3: $241M Revenue (TTM), FY24 Q4: $228.6M Revenue (TTM), FY25 Q1: $214.1M Revenue (TTM), FY25 Q2: $219.4M Revenue (TTM), FY25 Q3: $226.7M Revenue (TTM), FY25 Q4: $213.6M Revenue (TTM), FY26 Q1: $216.8M Revenue (TTM), FY26 Q2: $186.2M Revenue (TTM), FY26 Q3: $176.1M $176.1M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $306.9M
FY24 Q1 $277.5M
FY24 Q2 $264.8M
FY24 Q3 $241M
FY24 Q4 $228.6M
FY25 Q1 $214.1M
FY25 Q2 $219.4M
FY25 Q3 $226.7M
FY25 Q4 $213.6M
FY26 Q1 $216.8M
FY26 Q2 $186.2M
FY26 Q3 $176.1M
Revenue growth, TTM YoY Amarin Corp plc\uk
-30% -20% -10% 0% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: -16.9% Revenue growth, TTM YoY, FY24 Q1: -23.0% Revenue growth, TTM YoY, FY24 Q2: -23.5% Revenue growth, TTM YoY, FY24 Q3: -25.3% Revenue growth, TTM YoY, FY24 Q4: -25.5% Revenue growth, TTM YoY, FY25 Q1: -22.8% Revenue growth, TTM YoY, FY25 Q2: -17.2% Revenue growth, TTM YoY, FY25 Q3: -5.9% Revenue growth, TTM YoY, FY25 Q4: -6.5% Revenue growth, TTM YoY, FY26 Q1: 1.2% Revenue growth, TTM YoY, FY26 Q2: -15.1% Revenue growth, TTM YoY, FY26 Q3: -22.3% -22.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -16.9%
FY24 Q1 -23.0%
FY24 Q2 -23.5%
FY24 Q3 -25.3%
FY24 Q4 -25.5%
FY25 Q1 -22.8%
FY25 Q2 -17.2%
FY25 Q3 -5.9%
FY25 Q4 -6.5%
FY26 Q1 1.2%
FY26 Q2 -15.1%
FY26 Q3 -22.3%
Operating margin (TTM) Amarin Corp plc\uk
-60% -40% -20% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -22.0% Operating margin (TTM), FY24 Q1: -23.0% Operating margin (TTM), FY24 Q2: -15.3% Operating margin (TTM), FY24 Q3: -18.3% Operating margin (TTM), FY24 Q4: -40.2% Operating margin (TTM), FY25 Q1: -44.4% Operating margin (TTM), FY25 Q2: -50.3% Operating margin (TTM), FY25 Q3: -42.5% Operating margin (TTM), FY25 Q4: -23.5% Operating margin (TTM), FY26 Q1: -20.6% Operating margin (TTM), FY26 Q2: -21.9% Operating margin (TTM), FY26 Q3: -18.2% -18.2%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -22.0%
FY24 Q1 -23.0%
FY24 Q2 -15.3%
FY24 Q3 -18.3%
FY24 Q4 -40.2%
FY25 Q1 -44.4%
FY25 Q2 -50.3%
FY25 Q3 -42.5%
FY25 Q4 -23.5%
FY26 Q1 -20.6%
FY26 Q2 -21.9%
FY26 Q3 -18.2%
FCF margin (TTM) Amarin Corp plc\uk
-20% -10% 0% 10% 20% 30% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 2.2% FCF margin (TTM), FY24 Q1: 0.5% FCF margin (TTM), FY24 Q2: -3.3% FCF margin (TTM), FY24 Q3: -7.6% FCF margin (TTM), FY24 Q4: -13.6% FCF margin (TTM), FY25 Q1: -14.4% FCF margin (TTM), FY25 Q2: -5.3% FCF margin (TTM), FY25 Q3: -9.6% FCF margin (TTM), FY25 Q4: 3.1% FCF margin (TTM), FY26 Q1: 11.8% FCF margin (TTM), FY26 Q2: 8.4% FCF margin (TTM), FY26 Q3: 21.3% 21.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 2.2%
FY24 Q1 0.5%
FY24 Q2 -3.3%
FY24 Q3 -7.6%
FY24 Q4 -13.6%
FY25 Q1 -14.4%
FY25 Q2 -5.3%
FY25 Q3 -9.6%
FY25 Q4 3.1%
FY26 Q1 11.8%
FY26 Q2 8.4%
FY26 Q3 21.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 26 54 82 130 181 229 430 614 583 369 307 229 214 176
Gross profit 14 34 54 96 136 175 334 483 462 242 166 81 121 72
EBITDA −182 −96 −98 −65 −45 −108 −24 −19 11 −105 −67 −92 — —
Operating income −182 −96 −98 −66 −46 −108 −24 −20 11 −106 −68 −92 −50 −32
Net income −166 −56 −115 −86 −68 −116 −23 −18 8 −106 −59 −82 −39 −19
Diluted EPS — −$7.20 — −$8.20 −$5.00 −$7.80 −$1.40 −$1.00 $0.40 −$5.20 −$3.00 −$4.00 −$1.80 −$0.91
Growth (year on year)
Revenue — +105.7% +50.8% +59.1% +39.2% +26.6% +87.5% +42.9% −5.0% −36.7% −16.9% −25.5% −6.5% −22.3%
Margins
Gross margin 54.8% 62.2% 65.9% 73.6% 75.2% 76.2% 77.7% 78.6% 79.2% 65.7% 53.9% 35.6% 56.6% 40.9%
EBITDA margin −690.1% −176.7% −119.9% −50.3% −25.1% −47.2% −5.6% −3.1% 1.9% −28.5% −22.0% −40.1% — —
Operating margin −691.1% −177.0% −120.1% −50.4% −25.2% −47.2% −5.6% −3.2% 1.8% −28.7% −22.0% −40.2% −23.5% −18.2%
Net margin −630.8% −104.0% −140.9% −66.4% −37.5% −50.8% −5.3% −2.9% 1.3% −28.7% −19.3% −35.9% −18.2% −10.9%
Free-cash-flow margin −722.4% — −102.8% −55.2% −18.1% −41.3% −2.8% −3.6% −11.4% −48.8% 2.2% −13.6% 3.1% 21.3%
Cash flow
Cash from operations −190 −75 −84 −72 −33 −95 −9 −22 −67 −180 7 −31 7 37
Capital spending 0 — 0 0 0 0 2 0 0 0 0 0 0 0
Free cash flow −190 — −84 −72 −33 −95 −12 −22 −67 −180 7 −31 7 37
Stock-based pay 15 9 14 14 14 19 31 46 37 26 16 18 14 7
Free cash flow after stock pay −205 — −98 −85 −47 −114 −43 −68 −103 −206 −9 −49 −7 30
Balance sheet
Cash 192 120 107 98 74 249 645 187 219 218 199 121 135 157
Total debt 101 105 104 101 93 80 50 0 0 0 0 0 0 0
Net debt (negative = net cash) −91 −15 −3 3 20 −169 −594 −187 −219 −218 −199 −121 −135 −157
Diluted shares 8m 9m 9m 11m 14m 15m 17m 19m 20m 20m 20m 21m 21m 21m
Returned to shareholders
Buybacks — — 0 — — — — — — — — — — —
Total returned — — 0 — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $634m
Short-term assets $613mLonger-term assets $21m
What it owes, and who funded it · $634m
Short-term liabilities $175mLonger-term liabilities $15mShareholders' equity $444m
  • Short-term assets cover short-term liabilities $613m of assets due within a year against $175m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $613m short-term assets against $15m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Amarin Corp plc\uk's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.5%
year over year
R&D spending
10.8%
of revenue
Sales & admin spending
44.1%
of revenue
Days sales outstanding
231 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated AMRN CRON KMDA BTMD OGI HRTX Median
Revenue, last 12 months $176m $179m $180m $184m $185m $151m $276m
Revenue growth, last 12 months −22.3% 37.5% 12.1% −7.8% 57.8% 1.0% 9.9%
Revenue growth, 3-year average −18.3% 30.3% — 0.5% — 8.6% 5.5%
Revenue growth, latest quarter −20.4% 58.4% — −9.5% — 1.3% 6.5%
Gross margin 40.9% 45.9% 42.3% — 34.8% 70.1% 62.0%
Operating margin −18.2% −1.4% 14.5% 8.0% −5.9% −7.2% −5.9%
Operating margin, 3-year average −26.3% −38.9% 7.0% 13.9% — −13.5% −7.4%
Net margin −10.9% 39.1% 11.2% 3.2% −9.6% −22.5% −7.3%
Cash from operations / revenue 21.3% 33.5% 14.1% 13.3% −2.9% −7.7% 10.2%
Free-cash-flow margin 21.3% 27.8% 13.2% 10.8% −9.5% −8.0% 8.6%
Free-cash-flow margin, 3-year average 1.3% 11.1% 1.7% 13.2% — −47.0% 7.4%
Stock pay / revenue 4.2% 3.6% 0.5% 4.5% 1.6% 7.4% 3.6%
Change in share count 1.5% −2.1% 0.9% 3.3% 34.0% 5.9% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -22.3% 10.0% 65 of 74
Change in growth rate Growth -7.2pp -0.3pp 54 of 74
Gross margin Profitability 40.9% 59.8% 42 of 59
Operating margin Profitability -18.2% -5.9% 43 of 67
Net margin Profitability -10.9% -7.3% 43 of 75
Free-cash-flow margin Cash generation 21.3% 10.1% 17 of 74
Stock pay as % of revenue Cash generation 4.2% 3.6% 41 of 69
Change in share count Balance sheet 1.5% 1.5% 32 of 62
Days sales outstanding Balance sheet 231 days 72 days 56 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $183M 85.5% ▼ 10.7%
Licensing and Royalty $30.9M 14.5% ▲ 28.6%

From Amarin Corp plc\uk's 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$73.4M
Institutions reporting
80
Shares held vs prior quarter
▲ 0.6%
Positions opened / closed
20 / 7

Top buyers and sellers, Q2 2026: 35 institutions bought and 20 sold ; the biggest buyer was Brooklands Fund Management Ltd (+177K shares) and the biggest seller Point72 Asset Management, L.P (−241K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sarissa Capital Management LP $26.7M 1.7M 36.3% 0.0%
Acadian Asset Management LLC $11.5M 721K 15.6% ▲ 13.2%
Kynam Capital Management, LP $8.5M 533K 11.6% ▲ 12.8%
Morgan Stanley $3.6M 224K 4.9% ▼ 23.7%
Waterfront Wealth Inc. $3.2M 214K 4.3% ▲ 5.2%
Brooklands Fund Management Ltd $2.7M 177K 3.7% New
Eversept Partners, LP $2.3M 145K 3.2% ▼ 1.6%
Millennium Management LLC $1.8M 116K 2.5% ▼ 61.5%
Two Sigma Investments, LP $1.6M 101K 2.2% ▼ 6.5%
Citadel Advisors LLC $1.5M 95K 2.1% ▲ 18.4%
BNP Paribas Financial Markets $1.1M 72K 1.6% ▼ 4.9%
Lcm Capital Management Inc $818,710 51K 1.1% ▲ 18.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Amarin Corp plc\uk's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 14, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 29, 2026
  • April 29, 2026
  • February 25, 2026
  • January 8, 2026
  • October 29, 2025

Recent SEC filings

Data status

When each part of this page on Amarin Corp plc\uk was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Amarin Corp plc\uk in brief

What does Amarin Corp plc\uk do?
Amarin Corp plc\uk is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Amarin Corp plc\uk's stock ticker?
Amarin Corp plc\uk trades under the ticker AMRN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Amarin Corp plc\uk's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Amarin Corp plc\uk reported revenue of $176M, 22.3% lower than a year earlier, according to its SEC filings.
What is Amarin Corp plc\uk's free cash flow?
Amarin Corp plc\uk's free-cash-flow margin is 21.3% of revenue over the trailing twelve months, ranking 17 of the 74 pharmaceuticals companies we cover.
Who are Amarin Corp plc\uk's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sarissa Capital Management LP, Acadian Asset Management LLC and Kynam Capital Management, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Amarin Corp plc\uk's market cap?
On November 2, 2026, Amarin Corp plc\uk's market capitalisation was about $255M and net debt of -$157M. Market figures come from third-party market data and may be delayed.
Who are Amarin Corp plc\uk's competitors?
In our Pharmaceuticals peer group, the companies closest to Amarin Corp plc\uk are Cronos Group Inc., Kamada LTD, Biote Corp., Organigram Global Inc. and Heron Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Amarin Corp plc\uk's.
When is Amarin Corp plc\uk's next earnings date?
Around January 14, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Amarin Corp plc\uk announces its own schedule.